AMLX

NASDAQ 已收盘

Amylyx Pharmaceuticals

26.20 USD
▼-0.42-1.58%
盘后 26.71 +1.95%
2026-11-19
市值
$3.35B
市盈率
—
EPS
-1.45
股息率
—
52 周区间
10.83 – 41.14
成交量
1.76M
Beta
-0.08
目标价
43.00
52W 低 10.8352W 高 41.14
价格走势

公司简介

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas...

关联新闻